Active, not recruitingPhase 2NCT01522976
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Studying Chronic myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Mikkael A Sekeres, MDSWOG Cancer Research Network
- Intervention
- Azacitidine(drug)
- Enrollment
- 282 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2026
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States
- Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- Kaiser Permanente-Richmond, Richmond, California, United States
- Kaiser Permanente-South Sacramento, Sacramento, California, United States
- Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States
- Kaiser Permanente-San Francisco, San Francisco, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01522976 on ClinicalTrials.govOther trials for Chronic myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07071155Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT07512882Cohort of Patients With Chronic Myelomonocytic LeukemiaGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGPHASE2NCT06815003Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningCity of Hope Medical Center
- RECRUITINGPHASE2NCT06597734A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative NeoplasmM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06543381Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantCity of Hope Medical Center
- RECRUITINGPHASE3NCT06647862IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- RECRUITINGPHASE1, PHASE2NCT06159491Pacritinib in CMMLDouglas Tremblay
- RECRUITINGPHASE1NCT06218628Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionFox Chase Cancer Center